Human Delta-like protein 1 (DLL1) ELISA Kit

Category: Assay Kits
Catalog
AE47124HU
(Ships in 5-10 business days)

Questions? Contact us

Call (800) 832-2611

arp-guarantee
- +
$0.00
More Information
Product Name Human Delta-like protein 1 (DLL1) ELISA Kit
Description DLL1 is a human homolog of the Notch Delta ligand and is a member of the delta/serrate/jagged family. It plays a role in mediating cell fate decisions during hematopoiesis. It may play a role in cell-to-cell communication. Sequence analysis predicted that the 723-amino acid DLL1 transmembrane protein, which is 88% identical to the mouse Dll1 protein, has a DSL domain followed by 8 tandem EGF-like repeats and a short cytoplasmic C-terminal region. Northern blot analysis revealed strongest expression of 4.0- and 4.6-kb transcripts in heart and pancreas, with lower expression in brain and muscle and almost no expression in placenta, lung, liver, and kidney. In situ hybridization analysis indicated upregulated expression of DLL1 in squamous cell carcinoma and in situ and invasive adenocarcinoma. This assay has high sensitivity and excellent specificity for detection of Human DLL1. No significant cross-reactivity or interference between Human DLL1 and analogues was observed.
Synonyms DELTA1, DL1, Delta, delta-like 1|delta-like 1 protein
Method Sandwich ELISA
Detection Range 0.156-10 ng/mL
Sensitivity 0.056 ng/mL
Reactivity Human
Sample Types Serum, Plasma, Other biological fluids.
Background DLL1 is a human homolog of the Notch Delta ligand and is a member of the delta/serrate/jagged family. It plays a role in mediating cell fate decisions during hematopoiesis. It may play a role in cell-to-cell communication.
Sequence analysis predicted that the 723-amino acid DLL1 transmembrane protein, which is 88% identical to the mouse Dll1 protein, has a DSL domain followed by 8 tandem EGF-like repeats and a short cytoplasmic C-terminal region. Northern blot analysis revealed strongest expression of 4.0- and 4.6-kb transcripts in heart and pancreas, with lower expression in brain and muscle and almost no expression in placenta, lung, liver, and kidney. In situ hybridization analysis indicated upregulated expression of DLL1 in squamous cell carcinoma and in situ and invasive adenocarcinoma.
Supplier Abebio

All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.